Skip to main content
Article
An Atypical Presentation of Neuroleptic Malignant Syndrome
West Florida Division GME Research Day 2020
  • Rudy Forte, HCA Healthcare
  • Shiwani Kamath, HCA Healthcare
  • Debra Angelo, HCA Healthcare
  • Johnathan Frunzi, HCA Healthcare
Division
West Florida
Hospital
Medical Center of Trinity
Specialty
Internal Medicine
Document Type
Poster
Publication Date
5-1-2020
Keywords
  • Neuroleptic malignant syndrome; Atypical NMS; Aripiprazole induced NMS; Afebrile NMS
Abstract

Neuroleptic Malignant Syndrome (NMS) is a rare, but potentially life threatening condition associated with dopamine blockade, particularly first-generation antipsychotics. The complex pathophysiology of NMS remains somewhat unclear and debatable as the symptoms are not fully explained by dopamine blockade alone.1 D2 dopamine receptor antagonism remains responsible for most cases of NMS, however a few cases have been reported in which little to no D2 blockade activity was present.1

This poster is about an atypical presentation of NMS.

Citation Information
Rudy Forte, Shiwani Kamath, Debra Angelo and Johnathan Frunzi. "An Atypical Presentation of Neuroleptic Malignant Syndrome" (2020)
Available at: http://works.bepress.com/johnathan-frunzi/13/